Beyond the Antagonism: Self-Labeled Xanthone Inhibitors as Modeled “Two-in-One” Drugs in Cancer Therapy-Reference-Cited by-同舟云学术

Beyond the Antagonism: Self-Labeled Xanthone Inhibitors as Modeled “Two-in-One” Drugs in Cancer Therapy

Published:2017-03-13 Issue:3 Volume:2 Page:873-889
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Yu Fu-Chao¹,Lin Xin-Rong,Liu Zhi-Cheng¹^ORCID,Zhang Ji-Hong,Liu Fei-Fei,Wu Wei,Ma Yu-Lu¹,Qu Wen-Wen,Yan Sheng-Jiao¹,Lin Jun¹^ORCID

Affiliation:

1. Key Laboratory of Medicinal Chemistry for Natural Resource (Ministry of Education), Yunnan Provincial Engineering Research Center in University for Crude Drugs and Pharmaceutical Intermediates, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China

Funder

Ministry of Education of the People's Republic of China

National Natural Science Foundation of China

Reserve Talent Foundation of Yunnan Province for Middle-aged and Young Academic and Technical Leaders

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsomega.6b00545

Reference32 articles.

1. Confocal Fluorescence Microscopy Studies of a Fluorophore-Labeled Dirhodium Compound: Visualizing Metal–Metal Bonded Molecules in Lung Cancer (A549) Cells